Skip to main content
. 2017 Dec 11;8(70):115179–115189. doi: 10.18632/oncotarget.23112

Figure 3. Survival data.

Figure 3

(A-C) TUBB3 in the cohort of all patients (n=280) using protein expression analysis: 16% 5-year survival rate in the group of high-level (strong) TUBB3 expression. Strong TUBB3 expression is correlated with shortened survival (p=0,0003). (B) TUBB3 in the group of patients without neoadjuvant treatment (surgery, only) (n=98): TUBB3 is correlated with advanced post-surgery tumor stage (p=0,0071). (C) Tumors with advanced local tumor stage according to clinical evaluation (cT3) and minor response to neoadjuvant treatment (n=160) (definition of minor response: more than 10% vital tumor cells. Minor response measured by pathologist at surgery specimen). High-levels of TUBB3 expression is correlated with shortened survival in the group of minor responders (p=0,0050). (D-F) TUBB3 in the cohort of all patients (n=280) using mRNA expression analysis: 17% 5-year survival rate in the group of high-level (strong) TUBB3 expression. Strong TUBB3 expression is correlated with shortened survival (p=0,0002). (E) TUBB3 in the group of patients without neoadjuvant treatment (surgery, only) (n=98): TUBB3 is correlated with advanced post-surgery tumor stage (p=0,0304). (F) Tumors with advanced local tumor stage according to clinical evaluation (cT3) and minor response to neoadjuvant treatment (n=161) (definition of minor response: more than 10% vital tumor cells. Minor response measured by pathologist at surgery specimen). High-levels of TUBB3 expression is correlated with shortened survival in the group of minor responders (p=0,0055).